1-3 of 3
James Farrell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Symptomatic Progression Free Survival (SPFS): A New Endpoint for Multiple Myeloma (MM) Combining Patient-Reported Outcomes (PROs) and Progression-Free Survival (PFS)

Martin K. Kortüm, Sebastian Theurich, James Farrell, Joseph C. Cappelleri, Olivia Ashman, Shanti Neff-Baro, Aline Gauthier, Khalil Jewiti-Rigondza, Christof Scheid
Journal: Blood
Blood (2024) 144 (Supplement 1): 3322.
https://doi.org/10.1182/blood-2024-204074
Published: 2024
Journal Articles

Examining Discrepancies in Perspectives of Healthcare Providers and Patients with Relapsed/Refractory Multiple Myeloma on Novel Therapies across Diverse Clinical Landscapes: An International Prospective Study

Sikander Ailawadhi, Yelak Biru, Solène Clavreul, Maite San Miguel, Nicolas Cormier, Anna Sato, Cathy Zeanah, James Farrell, Erinn Hoag Goldman, Rakesh Popat
Journal: Blood
Blood (2024) 144 (Supplement 1): 3658.
https://doi.org/10.1182/blood-2024-208007
Published: 2024
Journal Articles

Matching-Adjusted Indirect Comparisons of Efficacy Outcomes in Patients with Relapsed and Refractory Multiple Myeloma for Idecabtagene Vicleucel (KarMMa) Versus Selinexor Plus Dexamethasone (STORM Part 2) and Belantamab Mafodontin (DREAMM-2): Updated Analysis with Longer Follow-up

Paula Rodríguez-Otero, Ali Mojebi, Dieter Ayers, Devender Dhanda, James Farrell, Faith E. Davies, Michel Delforge, Katja Weisel, Kevin Towle, Tom Marshall, Clyde Caisip, Shannon Cope
Journal: Blood
Blood (2021) 138 (Supplement 1): 1978.
https://doi.org/10.1182/blood-2021-145321
Published: 2021